Abstract
Exceeding interest arose in combining targeted therapies for the treatment of metastatic colorectal cancer as a result of impressive results reported on a small phase II study (BOND2). Consequently, clinical trial designs quickly adopted combined biologic therapy as a means to enhance treatment efficacy by blocking potentially two different signal transduction pathways. Recent data has been reported on the role of combined targeted therapies as well as ongoing trials. This review summarizes the potential preclinical rationale for combination targeted therapies in the treatment of colorectal cancer, currently available data, and the role of potential surrogate markers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
